US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

38.12

+0.07000.18%

Post-market: 38.120.00000.00%19:30 EDT

Volume:187.41K

Turnover:7.14M

Market Cap:3.29B

PE:6.16

High:38.36

Open:38.29

Low:37.75

Close:38.05

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.72

T/O Rate:1.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.60

PE(LYR):68.68

Loading ...

Overview Company News Filings

BioCardia Q1 net loss narrows as expenses decline

Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Blockchain Digital Infrastructure turns to Q1 FY26 net loss of USD 273,198; revenue rises 9% to USD 4.9 million

GMO AD Partners Flags Q1 2026 Results and Strategy Priorities

FCC grants Verizon, U.S. Celluar applications to assign spectrum licenses

Verizon Wireless Obtains Approval From FCC for Array Digital's Spectrum Licenses

MT Newswires Live

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Array Digital Infrastructure Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $52 From $54

THOMSON REUTERS

Press Release: Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Press Release: Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents

Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Array Digital Infrastructure Inc reports results for the quarter ended March 31 - Earnings Summary

Array Digital Q1 Net Income, Revenue Rise; Maintains 2026 Revenue Guidance

MT Newswires Live

GUIDANCE: (AD) Array Digital Infrastructure Expects 2026 Total Operating Revenue Range $200M-$215M, vs. FactSet Est of $209.M

MT Newswires Live

Telephone and Data Systems Submits Proposal to Acquire Array Digital Infrastructure in All-Stock Deal; Array Forms Committee

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/AD/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":38.12,"timestamp":1789156800000,"preClose":38.05,"halted":0,"volume":187406,"hourTrading":{"tag":"盘后","latestPrice":38.12,"preClose":38.12,"latestTime":"19:30 EDT","volume":1047,"amount":39911.64,"timestamp":1789169408128,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0018396846254927803,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Market Closed","change":0.07,"latestTime":"09-11 16:00:00 EDT","open":38.29,"high":38.36,"low":37.75,"amount":7144444.830108001,"amplitude":0.016032,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":38.05,"postHourTrading":{"tag":"盘后","latestPrice":38.12,"preClose":38.12,"latestTime":"19:30 EDT","volume":1047,"amount":39911.64,"timestamp":1789169408128,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7206132626798357,"impliedVol":0.3382,"impliedVolPercentile":0.592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.7206132626798357,"shares":86379877,"dividePrice":0,"high":38.36,"amplitude":0.016032,"preClose":38.05,"low":37.75,"week52Low":33.71,"pbRate":"2.60","psRate":"15.42","week52High":60.82,"institutionHeld":0.3358,"latestPrice":38.12,"eps":6.185934,"divideRate":0,"volume":187406,"delay":0,"ttmEps":6.185934,"open":38.29,"prevYearClose":53.62,"prevWeekClose":38.5,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.73,"twentyDayClose":35.7,"sixtyDayClose":39.69,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-11","current":6.162368,"percent":0.3,"low":-273.92211,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"high":320.844562,"avg":57.30785,"sd":169.935215,"marketCap":3290525950},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950}],"updateTime":1789284088430},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635081017","title":"BioCardia Q1 net loss narrows as expenses decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081017?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:08","pubTimestamp":1778846883,"startTime":"0","endTime":"0","summary":"BioCardia Q1 net loss narrows as expenses declineOverviewUS cellular therapeutics developer's Q1 net loss narrowed from prior yearResearch and development, and SG&A expenses both declined yr/yrCompany","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","TDS","BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089930","title":"Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089930","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089930?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in. -- PD open-label extension  study: 40% of patients enrolled; full. -- New Drug Application  for buntanetap as a symptomatic treatment for. AD is expected in early 2027 and as a potential disease-modifying. \"We saw strong momentum across both our AD and PD programs in the first quarter,\" said Maria Maccecchini, Ph.D., President and CEO of Annovis. \"Our Phase 3 AD clinical trial achieved significant enrollment growth, keeping us firmly on track to complete randomization of patients in summer 2026 and deliver first top-line results in early 2027. Simultaneously, we launched a PD OLE study and have been encouraged by the robust interest from both returning and new patients. This year is pivotal: we expect to generate substantive clinical data across both indications that will anchor our regulatory path toward an NDA submission for buntanetap.\". -- Screening: On May 15, 2026, Annovis closed enrollment to new partici","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1169590202.USD","BK4132","DBS","AD","ANVS","PD","BK4139","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086190","title":"Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086190","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086190?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":"Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295720/0/en/Kymera-Therapeutics-Announces-Presentations-on-KT-621-a-First-In-Class-Oral-STAT6-Degrader-at-the-Society-for-Investigative-Dermatology-and-American-Thoracic-Society-Congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BP","BK4132","PN","SID","BK4588","LU1162221912.USD","BK4096","LU1829250122.USD","ATS","BPH","LU0300736062.USD","BK4107","BK4161","LU0541502299.USD","LU0162691827.USD","LU0320765646.SGD","LU0300736492.USD","SG9999004220.SGD","BK4117","BK4201","LU0072461881.USD","BK4006","BK4139","BK4115","KT","AD","LU0541501648.USD","LU0006061336.USD","KYMR","AFG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635096088","title":"Blockchain Digital Infrastructure turns to Q1 FY26 net loss of USD 273,198; revenue rises 9% to USD 4.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635096088","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635096088?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:14","pubTimestamp":1778840090,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure posted Q1 revenue of USD 4.9 million, up 9%.Net results turned to a loss of USD 273,198 from profit, while operating results swung to a loss of about USD 0.3 million.Gross margin narrowed 15 percentage points to 12%, as cost of revenues climbed to USD 4.34 million.Cash rose to USD 1.25 million, with operating cash flow of USD 1.27 million.Completed business combination with Signing Day Sports on March 16, 2026; began trading on NYSE American March 17 under ticker AIB.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blockchain Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8m7bLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","TDS","AIB","BK4116","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635770611","title":"GMO AD Partners Flags Q1 2026 Results and Strategy Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2635770611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635770611?lang=en_us&edition=fundamental","pubTime":"2026-05-15 15:18","pubTimestamp":1778829491,"startTime":"0","endTime":"0","summary":"GMO AD Partners Inc. ( ($JP:4784) ) has provided an update. GMO AD Partners Inc., under the umbrella of GMO Internet, disclosed headline informatio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-flags-q1-2026-results-and-strategy-priorities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-flags-q1-2026-results-and-strategy-priorities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","GMO","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635477927","title":"FCC grants Verizon, U.S. Celluar applications to assign spectrum licenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635477927","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635477927?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:31","pubTimestamp":1778783505,"startTime":"0","endTime":"0","summary":"The FCC released an Order approving the applications of Verizon Wireless (VZ) and United States Cellular Corporation (AD) for consent to assign cer...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fcc-grants-verizon-u-s-celluar-applications-to-assign-spectrum-licenses-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fcc-grants-verizon-u-s-celluar-applications-to-assign-spectrum-licenses-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066051498.USD","UZD","LU2210149790.SGD","BK4585","LU0942090050.USD","LU2210150020.SGD","BK4534","HK0000819398.USD","LU0985481810.HKD","LU1621768206.USD","LU1162221912.USD","LU1430594728.SGD","LU1066051811.HKD","LU1059921491.USD","BK4533","LU1621767737.EUR","UZE","BK4132","LU0225284248.USD","BK4515","BK4550","LU0265550946.USD","BK4581","VZ","LU1066051225.USD","LU1366192091.USD","LU2381873111.SGD","LU0868494617.USD","IE00BSNM7G36.USD","LU1914381329.SGD","LU0265550359.USD","BK4559","BK4115","LU0321505439.SGD","LU2095319765.USD","LU1116320737.USD","LU1116320901.HKD","LU0306806265.USD","LU1621767810.EUR","LU1621768115.EUR","AD","LU0306807586.USD","LU1066053197.SGD","LU2384288077.EUR","BK4588","LU0320765646.SGD","LU0868494708.USD","LU1571399168.USD","LU1699723380.USD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635744516","title":"Verizon Wireless Obtains Approval From FCC for Array Digital's Spectrum Licenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635744516","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635744516?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:44","pubTimestamp":1778777086,"startTime":"0","endTime":"0","summary":"Verizon Communications  and Array Digital Infrastructure  have obtained approval from the US Federal Communications Commission to assign several cellular, AWS-1, AWS-3, and PCS licenses from Array subsidiaries to Verizon Wireless, the commission said in a memorandum Thursday.The Verizon Communications subsidiary is targeting to acquire zero to 25 megahertz of cellular spectrum, zero to 20 megahertz of AWS-1 spectrum, zero to 10 megahertz of AWS-3 spectrum, and zero to 20 megahertz of PCS spectrum in 618 counties across 19 states, covering roughly 8% of the US population, according to the memorandum.The risk of public interest harm due to the applications is low, the commission said, adding that the transaction \"is likely to produce public interest benefits that will enable Verizon Wireless to provide a better overall experience to its customers.\"Price: 47.13, Change: -0.08, Percent Change: -0.17","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000819398.USD","LU1621768115.EUR","LU1066053197.SGD","LU1914381329.SGD","LU0098860793.USD","VZ","LU1621767810.EUR","LU0320765646.SGD","LU0306807586.USD","LU1699723380.USD","BK4515","LU1059921491.USD","BK4018","LU1066051498.USD","LU0321505439.SGD","LU0265550359.USD","AD","BK4533","LU0868494708.USD","BK4581","LU1366192091.USD","LU2210149790.SGD","LU2065732104.USD","LU1430594728.SGD","LU0306806265.USD","LU0868494617.USD","IE00BSNM7G36.USD","LU0225284248.USD","BK4534","BK4115","LU1585245621.USD","LU1066051811.HKD","BK4559","LU2210150020.SGD","LU1621767737.EUR","LU2384288077.EUR","LU0321505868.SGD","LU1116320901.HKD","LU2095319765.USD","LU0985481810.HKD","BK4550","LU1066051225.USD","BK4132","LU1571399168.USD","BK4585","LU1162221912.USD","BK4588","LU0942090050.USD","SPB","LU2381873111.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712778","title":"INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712778","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712778?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"BOCA RATON, FL, May  14, 2026  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Dr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294832/0/en/INmune-Bio-Receives-FDA-Fast-Track-Designation-for-XPro1595-in-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","LABU","MCI","INMB","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758067","title":"Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294435/0/en/Longeveron-Announces-2026-First-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4575","AD","MSC","BK4139","LGVN","IND","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788874","title":"Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788874","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635788874?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:01","pubTimestamp":1778666460,"startTime":"0","endTime":"0","summary":"- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293787/36461/en/Voyager-ASGCT-Late-Breaker-Single-IV-Dose-of-VY1706-Well-Tolerated-Reduced-Tau-in-3-Month-GLP-Toxicology-Data-Clinical-Trial-in-Alzheimer-s-Disease-Expected-H2-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4135","AD","BBB","BK4144","IND","CNS","GLP","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634214783","title":"Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634214783","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634214783?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:00","pubTimestamp":1778590800,"startTime":"0","endTime":"0","summary":"– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data fr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292887/0/en/Connect-Biopharma-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211896","title":"Array Digital Infrastructure Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $52 From $54","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211896?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:31","pubTimestamp":1778589073,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P165:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634184812","title":"Press Release: Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634184812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634184812?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"-- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to. investigate sabirnetug  for the treatment of early Alzheimer's. -- Lead clinical candidate IND filing in Acumen's EBDTM (enhanced brain. -- Cash, cash equivalents and marketable securities of $128.4 million as of. Mar. 31, 2026, expected to support current clinical and operational. \"In the first quarter of 2026 Acumen remained steadfast in the execution of our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD. Topline results are expected late this year and are anticipated to provide important evidence in support of the amyloid beta oligomer hypothesis within the broader field of anti-amyloid antibodies,\" said Daniel O'Connell, Chief Executive Officer of Acumen. \"In the near term, we expect to execute our option to license as many as two candidates in our EBD program. We are excited about the optionality this innovative blood-brain barrier tec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4139","BK4604","R","BETA","ABOS","BK4187","BK4099","BK4232","BK4555","BK4588","TM","BK4022","03160","BK4585","BK4132","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634322822","title":"Press Release: Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634322822","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634322822?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis  on Track, Topline Results Expected Mid-2026. Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group. Turn Therapeutics Inc. , a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates.\"The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially,\" said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. \"With the Avenue Capital facility now in place, we believe the Company is well positioned to advance our clinical programs through multiple near-term catalysts while maintaining focus on disciplined execution. Our Phase 2 trial evaluating GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an independent committee expected to assess conditional ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4132","AD","LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634605236","title":"Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2634605236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634605236?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:00","pubTimestamp":1778518800,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 11, 2026 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin ndeg56  the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am , at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.All documentation regarding this Combined Shareholders' Meeting will be available to shareholders in accordance with existing regulations on the Company's website, in the Financials section under the Combined Shareholders Meeting tab .The Combined Shareholders' Meeting will be broadcasted live and will be available on the Company's website in the same section. A recording of the Combined Shareholders' Meeting will be available on the Company's website within the time frame specified by regulatio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","BK4081","HE","BK4099","BK4588","AD","CET","BK4022","BK4555","EMA","PBC","CCA","BK4132","BK4585","03160","BK4232","BK4604","TM","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928808","title":"Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928808","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928808?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:01","pubTimestamp":1778497260,"startTime":"0","endTime":"0","summary":"Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis  expected later this year:. - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD. - APEX Phase 2 Part B 16-week data in AD expected in Q2 2026. - Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis  expected later this year. Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment. SAN FRANCISCO and BOSTON, May 11, 2026  -- Apogee Therapeutics, Inc. , a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and report","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","PRGS","AD","BK4139","LU2065732104.USD","BK4132","BK4097","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633683714","title":"Array Digital Infrastructure Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633683714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633683714?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254214,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc reports results for the quarter ended March 31 - Earnings SummaryArray Digital Infrastructure Inc AD.N reported quarterly adjusted earnings of $1.67 per share for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","TDS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633552124","title":"Array Digital Q1 Net Income, Revenue Rise; Maintains 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2633552124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633552124?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:06","pubTimestamp":1778241996,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure  reported Q1 net income from continuing operations Friday of $2.08 per diluted share, up from $0.05 a year earlier.Two analysts polled by FactSet expected $0.91.Total operating revenue for the quarter ended March 31 was $52 million, up from $27 million a year earlier.Four analysts expected revenue of $54.3 million.The company maintained its full-year 2026 total operating revenue of $200 million to $215 million. Analysts expect revenue of $209.4 million.The company's shares were up more than 2% in recent premarket activity on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453908","title":"GUIDANCE: (AD) Array Digital Infrastructure Expects 2026 Total Operating Revenue Range $200M-$215M, vs. FactSet Est of $209.M","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453908","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453908?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:37","pubTimestamp":1778240275,"startTime":"0","endTime":"0","summary":"GUIDANCE: (AD) Array Digital Infrastructure Expects 2026 Total Operating Revenue Range $200M-$215M, vs. FactSet Est of $209.M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AD","TSS","DTCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633539774","title":"Telephone and Data Systems Submits Proposal to Acquire Array Digital Infrastructure in All-Stock Deal; Array Forms Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2633539774","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633539774?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:35","pubTimestamp":1778240119,"startTime":"0","endTime":"0","summary":"Telephone and Data Systems Submits Proposal to Acquire Array Digital Infrastructure in All-Stock Deal; Array Forms Committee","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TDS","DTCR","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":194,"code":"91000000","status":"200"}]}}